SOURCE: Bollinger Report

November 16, 2011 09:00 ET

Market Considerations in Europe Outlook - Featured Research on Netlist, Inc. and Cadence Pharmaceuticals, Inc.

NEW YORK, NY--(Marketwire - Nov 16, 2011) - Today, introduced featured coverage of Netlist, Inc. (NASDAQ: NLST) and Cadence Pharmaceuticals, Inc. (NASDAQ: CADX). Full research reports are available to readers at:

With the European Financial Stability Facility set to increase to $1.4 trillion, it marks a significant move forward to strengthen the safety net in place for Europe's most troubled countries. Private bondholders of Greek debt are settling at a 50% haircut as another $180 billion in fresh aid is set to arrive, enabling banks to recapitalize at a healthy 9% reserve. Overall, these measures will bring Greece's debt burden down to 120% of GDP by 2020. An important consideration is political commitment to this road map. Currently the global community appears to be on point with ECB's initiative, an outlook that should be sufficient to support markets around current levels.

Bollinger Report screened and selected Netlist, Inc. for its current position within the technology industry. Netlist, Inc. designs, manufactures and sells memory subsystems for the server, high performance computing and communications markets. A copy of this report featuring Netlist, Inc. (NASDAQ: NLST) is available at:

Bollinger Report is featuring Cadence Pharmaceuticals, Inc. for its changing role within the healthcare industry. Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing product candidates for use in the hospital setting. The Company has rights to one product candidate, Ofirmev, an intravenous formulation of acetaminophen for the management of pain and reduction of fever in adults and children. To download researches and analysis on Cadence Pharmaceuticals, Inc. (NASDAQ: CADX) we welcome investors to visit:

About Bollinger Report
Bollinger Report has come to be known among its peers as a trusted source of information for both investors and technical traders. Our online content is continually updated, bringing fresh new researches and analyses to the investment community.

Contact Information